Clinical trials: Ticagrelor
Healthy
Study to Evaluate the Safety, Tolerability, PK, and PD of PB2452 in Healthy Volunteers
This is a Phase 1, first-in-human, randomized, double-blind, placebo-controlled, single ascending dose, sequential group study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PB2452 with and…
- Trial name
- NCT03492385
- Testing
- PB2452 Infusion, Ticagrelor Oral Tablet - Pre-Treatment, Ticagrelor Oral Tablet - Pre-Treatment and Post-Treatment
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- SFJ Pharmaceuticals, Inc.
Healthy
Ticagrelor and Adenosine
Preclinical studies have shown that the P2Y12 receptor antagonist ticagrelor can increase the extracellular concentration of the endogenous nucleoside adenosine by inhibiting the cellular uptake of adenosine via the equilibrative…
- Trial name
- NCT01996735
- Testing
- Ticagrelor 180 mg single dose
- Where
- Netherlands
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Myocardial Infarction
Comparison of Ticagrelor Pharmacokinetics and Pharmacodynamics in STEMI and NSTEMI Patients
The purpose of the PINPOINT study is to compare pharmacokinetics (PK) and pharmacodynamics (PD) of ticagrelor in ST-elevation myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI) patients designated…
- Trial name
- PINPOINT (NCT02602444)
- Testing
- ticagrelor
- Where
- Poland
- Volunteers
- 73 people
- Sponsor
- Collegium Medicum w Bydgoszczy
Stable Coronary Artery Disease
A Pharmacodynamic Study With Ticagrelor in African American Patients
The purpose of this study is to assess the pharmacodynamic effect of ticagrelor in African American patients with stable coronary artery disease.
- Trial name
- NCT01523392
- Testing
- Ticagrelor, Clopidogrel
- Where
- 8 sites in United States
- Volunteers
- 50 people
- Sponsor
- AstraZeneca
Coronary Artery Disease, Coronary Artery Bypass Grafting
Ticagrelor-based De-escalation of Dual Antiplatelet Therapy After Coronary Artery Bypass Grafting
Ticagrelor-based De-escalation of Dual Antiplatelet Therapy After Coronary Artery Bypass Grafting trial (TOP-CABG trial) is a multicenter, randomized, double-blind, non-inferiority, parallel controlled trial.
- Conditions
- Coronary Artery Disease, Coronary Artery Bypass Grafting, Dual Antiplatelet Therapy, Bleeding
- Trial name
- TOP-CABG (NCT05380063)
- Testing
- De-escalated Dual Antiplatelet Therapy, Dual Antiplatelet Therapy
- Where
- China
- Volunteers
- 2,300 people
- Sponsor
- China National Center for Cardiovascular Diseases
Coronary Microvascular Disease, Ticagrelor
Effect of Ticagrelor and Clopidogrel on Coronary Microcirculation in Patients With Acute Myocardial Infarction
Of the patients diagnosed with ST-segment elevation myocardial infarction (STEMI) who underwent reperfusion therapy and have thrombolysis in myocardial infarction (TIMI) 3 flow, about 40% have flow alterations in the coronary…
- Conditions
- Coronary Microvascular Disease, Ticagrelor, Thrombolysis, Microbubble Contrasted Echocardiography
- Trial name
- NCT03104062
- Testing
- Microbubble Contrasted Echocardiography, Platelet Aggregability, Laboratory
- Where
- Brazil
- Volunteers
- 48 people
- Sponsor
- University of Sao Paulo General Hospital
ST-Elevation Myocardial Infarction
PraSugrel vs TicagrElor in ST-Elevation Myocardial Infarction paTients With Diabetes Mellitus
Dual antiplatelet therapy is essential in patients following ST-Elevation myocardial infarction (STEMI) with percutaneous coronary intervention (PCI) and drug eluting stent implantation.
- Trial name
- RESET 2D (NCT01531114)
- Testing
- ticagrelor, prasugrel
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Gennaro Sardella
Acute Coronary Syndrome
TicagRelor Or Clopidogrel in Severe and Terminal Chronic Kidney Disease Patients Undergoing PERcutaneous Coronary Intervention for an Acute Coronary Syndrome.
Ticagrelor is a potent and fast-acting P2Y12-ADP receptor antagonist recommended as first-line agent in ACS (2). This drug was associated with a 20% relative reduction in the rate of MACE in ACS patients undergoing PCI compared…
- Trial name
- TROUPER (NCT03357874)
- Testing
- Clopidogrel, Ticagrelor
- Where
- France
- Volunteers
- 259 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Platelet Reactivity
Low-dose of Ticagrelor and Standard-dose Clopidogrel on Platelet Effects in Chinese Patients With Stable CAD.
Ticagrelor has been demonstrated to provide a more rapid and more powerful inhibition of platelet aggregation compared with clopidogrel in coronary artery disease (CAD) patients.
- Trial name
- NCT03679091
- Testing
- low-dose ticagrelor, Clopidogrel
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Harbin Medical University
Acute Coronary Syndrome
ADHerence of ticagrelOr in Real World Patients With aCute Coronary Syndrome
Ticagrelor 90 mg twice daily treatment is recommended for 12 months in patients with acute coronary syndrome (ACS) and in patients undergoing coronary revascularization and conservative strategies.
- Trial name
- AD-HOC (NCT03129867)
- Testing
- Ticagrelor
- Volunteers
- 480 people
- Sponsor
- FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Acute Coronary Syndrome, Percutaneous Coronary Intervention
Optimized Antiplatelet Therapy on the Prognosis of ACS Patients With Non-predominant Coronary Artery Disease After PCI
The study is to evaluate the effect of optimized 12-month step-down antiplatelet therapy (APT) compared with standard 12-month dual antiplatelet therapy in clinical net adverse events, cardiovascular and cerebrovascular adverse…
- Trial name
- NCT04338919
- Testing
- Percutaneous coronary intervention, Ticagrelor plus aspirin
- Where
- China
- Volunteers
- 2,020 people
- Sponsor
- Fujian Medical University
Coronary Artery Disease, Diabetes Mellitus. Type 2
Comparison of TIcagrelor and Clopidogrel in Patients With Coronary Artery diseaSe and Type 2 Diabetes Mellitus (TICS-DM)
Patients with type 2 diabetes mellitus (T2DM), have a high prevalence of suboptimal response to clopidogrel (up to 40%). This impaired response to antiplatelet drugs has been consistently associated with a higher risk of adverse…
- Trial name
- TICS-DM (NCT02457130)
- Testing
- Ticagrelor, Clopidogrel
- Where
- 3 sites in Spain
- Volunteers
- 30 people
- Sponsor
- Spanish Society of Cardiology
Bioavailability Heathy Volunteers
Study to Investigate if the Uptake of Ticagrelor Into the Body Differs Depending on Method of Administration.
Study to investigate if the uptake of Ticagrelor into the body differs depending on method of administration.
- Trial name
- NCT01887626
- Testing
- Ticagrelor 90 mg whole tablet, Ticagrelor 90 mg tablet crushed, Dispersed ticagrelor 90 mg tablet suspended in water - nasogastric tube
- Where
- United Kingdom
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
Study to Assess Effect of Cyclosporine on the Blood Levels of Ticagrelor
The purpose of this study is to assess the effect of Cyclosporine on the blood levels of Ticagrelor.
- Trial name
- NCT01504906
- Testing
- cyclosporine, ticagrelor
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Coronary Artery Disease
Overcoming High On-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy With Ticagrelor
The primary objective is to determine the pharmacodynamic effect of ticagrelor dosing (180mg LD/ 90mg BID) at 2, 4 hours and 14 days in stable Coronary artery disease (CAD) patients who exhibit high-on prasugrel platelet…
- Trial name
- HEIGHTEN (NCT01869309)
- Testing
- Prasugrel, Ticagrelor
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- LifeBridge Health
Platelet Reactivity
Ticagrelor in Comparison to Prasugrel for Early Inhibition of Platelet Reactivity in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)
This is a single-center, randomized, single-blind, investigator-initiated, pharmacodynamic study with a parallel design. Patients with ST elevation myocardial infarction, undergoing primary percutaneous coronary intervention will…
- Trial name
- NCT01463163
- Testing
- Prasugrel, Ticagrelor
- Where
- Greece
- Volunteers
- 50 people
- Sponsor
- University of Patras
Gout, Coronary Artery Disease
Uric Acid Study in Healthy Male Volunteers
This study is being conducted to examine the effect of AZD6140 on the levels of certain chemicals in subjects' blood and urine.
- Trial name
- NCT00738842
- Testing
- AZD6140
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Peripheral Artery Disease (PAD)
Walking Effect of Long Term Ticagrelor in Subjects With PAD Who Have Undergone EVR
To compare the effect of ticagrelor versus aspirin on the change in peak walking time, evaluated on the graded treadmill test, from one to 26 weeks post-revascularization in patients with peripheral artery disease who have…
- Trial name
- TI-PAD EVR (NCT02227368)
- Testing
- Ticagrelor, Comparator
- Where
- 10 sites in United States
- Volunteers
- 40 people
- Sponsor
- AstraZeneca
Acute Coronary Syndrome
An Observational Prospective Study to Understand the Usage Pattern of Ticagrelor With ACS (Acute Coronary Syndrome)
The TREASURE observational study is designed to address the need to understand the usage pattern of Ticagrelor in real life scenario in large number of ACS (Acute Coronary Syndrome) patients in India.
- Trial name
- TREASURE (NCT02408224)
- Where
- 31 sites in India
- Volunteers
- 3,000 people
- Sponsor
- AstraZeneca
Acute Coronary Syndrome
Timing of Coronary Artery Bypass Surgery Among Patients With Acute Coronary Syndromes Initially on Ticagrelor
Ticagrelor, a more potent P2Y12 inhibitor, has been shown to reduce major adverse cardiac events (MACE) in acute coronary syndromes (ACS). It is increasingly used as a first line therapy in ACS.
- Trial name
- RAPID CABG (NCT02668562)
- Testing
- Early CABG (Day 2-3 after ticagrelor discontinuation), Delayed CABG (Day 5-7 after ticagrelor discontinuation)
- Where
- 2 sites in Canada
- Volunteers
- 143 people
- Sponsor
- Ottawa Heart Institute Research Corporation